Median OS was 13·0 months in the immunotherapy group versus 10·3months in the platinum–etoposide group.8 So the standard chemotherapy (EP) plus PD-L1 inhibitor (atezolizumab ordurvalumab) then flowed by PD-L1 inhibitor maintenance treatment was recommended forextensive-stage SCLC; however, the median OS was prolonged just only about 2 monthscompared with the standard chemotherapy.7-8 Whether bevacizumab with PD-L1 inhibitor plus chemotherapy would be anoptimal combination in extensive-stage SCLC needs more clinical trials. The gene discussed is CD274; the disease is small cell lung carcinoma.